MicroRNA-451 sensitizes lung cancer cells to cisplatin through regulation of Mcl-1.
As one of the most widely used chemotherapy drugs for lung cancer, chemoresistance of cisplatin (DPP) is one of the major hindrances in treatment of this malignancy. The microRNAs (miRNAs) have been identified to mediate chemotherapy drug resistance. MiR-451 as a tumor suppressor has been evaluated its potential effect on the sensitivity of cancer cells to DDP. However, the role of miR-451 in regulatory mechanism of chemosensitivity in lung cancer cells is still largely unknown. In this study, we first constructed a cisplatin-resistant A549 cell line (A549/DPP) accompanied with a decreased expression of miR-451 and an increased expression of Mcl-1in the drug resistant cells compared with the parental cells. Exogenous expression of miR-451 level in A549/DPP was found to sensitize their reaction to the treatment of cisplatin, which coincides with reduced expression of Mcl-1. Interestingly, Mcl-1 knockdown in A549/DPP cells increased the chemosensitivity to DPP, suggesting the dependence of Mcl-1 regulation in miR-451 activity. Moreover, miR-451 can restore cisplatin treatment response in cisplatin-resistant xenografts in vivo, while Mcl-1 protein levels were decreased. Thus, these findings provided that in lung cancer cells, tumor suppressor miR-451 enhanced DPP sensitivity via regulation of Mcl-1 expression, which could be served as a novel therapeutic target for the treatment of chemotherapy resistant in lung cancer.
Department of Thoracic Cardiovascular, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Dezhi
D
Cheng
Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, China.
Yi
Y
Xu
Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, China.
Changzheng
C
Sun
Department of Thoracic Cardiovascular, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China. zhif_he@126.com.
Zhifeng
Z
He
D000818:Animals; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000494:pharmacology*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D051379:Mice; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism*; D064549:Myeloid Cell Leukemia Sequence 1 Protein / Q000096:biosynthesis* / Q000235:genetics; D012334:RNA, Neoplasm / Q000235:genetics / Q000378:metabolism*; D023041:Xenograft Model Antitumor Assays
C579095:MCL1 protein, human; C531201:MIRN451 microRNA, human; D035683:MicroRNAs; D064549:Myeloid Cell Leukemia Sequence 1 Protein; D012334:RNA, Neoplasm; D002945:Cisplatin
Chemoresistance; Cisplatin; Lung cancer; Mcl-1; MiR-451
Curr Opin Oncol. 2016 Mar;28(2):97-103
26844984
BMC Cancer. 2012 Nov 21;12 :541
23171055
Gastroenterol Res Pract. 2012;2012:163284
22899903
Stem Cells. 2011 Nov;29(11):1661-71
21948564
J Cancer Prev. 2015 Mar;20(1):50-6
25853103
Eur J Cancer. 2014 Nov;50(17):3050-67
25310895
J Exp Clin Cancer Res. 2011 Feb 17;30:20
21329503
Int J Oncol. 2015 Apr;46(4):1844-8
25647738
Sci Rep. 2016 May 24;6:26643
27217294
Oncogene. 2011 May 19;30(20):2367-78
21258408
Oncotarget. 2016 Aug 2;7(31):49384-49396
27283902
Oncogene. 2014 Oct 2;33(40):4813-22
24166509
Am J Respir Crit Care Med. 2005 Sep 1;172(5):523-9
15961694
J Pathol. 2016 Aug;239(4):459-72
27171498
Med Sci Monit. 2015 Oct 30;21:3291-7
26516138
Oncol Lett. 2016 Apr;11(4):2566-2572
27073518
Asian Pac J Cancer Prev. 2013;14(6):3631-4
23886157
Mol Cell Biochem. 2015 Jul;405(1-2):73-9
25862460
PLoS One. 2014 Jan 22;9(1):e87006
24466313
Biol Open. 2016 Jun 15;5(6):669-77
27185265